Treatment of pancreatic cancer by intra-arterial injection of an emulsion of Lipiodol and bumetanide (an anti-glycolytic drug) in a porcine model: initial results

Yarmohammadi, Hooman; Aguirre, A. Gonzalez; Schook, Lawrence B.; Ziv, Etay; Erinjeri, Joseph P.; Brown, Karen T.; Srimathveeravalli, Govindarajan; O'Reilly, E.; Allen, Peter J.; Haaga, John R.; Solomon, Saul; Boas, F.

doi:10.1016/j.jvir.2016.12.598

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The artery supplying pig pancreatic cancer could be selectively catheterized using a standard 2.4 F microcatheter. Thus, the Oncopig pancreatic tumor model can be used to develop new image-guided therapies, such as transarterial embolization [30], local immunotherapy [31], and vascular targeted photodynamic therapy [32].…”

Section: Plos Onementioning

confidence: 99%

Induction and characterization of pancreatic cancer in a transgenic pig model

et al. 2020

View full text Add to dashboard Cite

Background Preclinical testing of new locoregional therapies for pancreatic cancer has been challenging, due to the lack of a suitable large animal model. Purpose To develop and characterize a porcine model of pancreatic cancer. Unlike small animals, pigs have similar physiology, drug dosing, and immune response to humans. Locoregional therapy in pigs can be performed using the same size catheters and devices as in humans. Methods The Oncopig is a transgenic pig with Cre-inducible TP53 R167H and KRAS G12D mutations. In 12 Oncopigs, CT-guided core biopsy of the pancreas was performed. The core biopsy was incubated with an adenoviral vector carrying the Cre recombinase gene. The transformed core biopsy was injected back into the pancreas (head, tail, or both). The resulting tumors (n = 19) were characterized on multi-phase contrast-enhanced CT, and on pathology, including immunohistochemistry. Angiographic characterization of the tumors was performed in 3 pigs. Results Pancreatic tumors developed at 19 out of 22 sites (86%) that were inoculated. Average tumor size was 3.0 cm at 1 week (range: 0.5-5.1 cm). H&E and immunohistochemical stains revealed undifferentiated carcinomas, similar to those of the pancreatobiliary system in

show abstract

Section: Plos Onementioning

confidence: 99%

Induction and characterization of pancreatic cancer in a transgenic pig model

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Thus, ethiodized oil serves as a tumor-targeting drug carrier. Similarly, intra-arterial ethiodized oil is also specifically retained in hepatocellular carcinoma (20), colorectal liver metastases (21), other liver tumors (22,23), and also in tumors outside the liver such as pancreatic (24,25) and renal (26) tumors. Ethiodized oil appears to specifically localize in tumors versus normal tissue but is nonspecific for the type of tumor.…”

Section: Discussionmentioning

confidence: 99%

Bronchial or Pulmonary Artery Chemoembolization for Unresectable and Unablatable Lung Metastases: A Phase I Clinical Trial

Boas¹,

Kemeny²,

Sofocleous³

et al. 2021

Radiology

View full text Add to dashboard Cite

M ost patients with lung metastases have unresectable disease (1). Patients with unresectable and unablatable lung metastases have poor survival and limited treatment options when the metastases stop responding to systemic chemotherapy (2).Transarterial chemoembolization (TACE) of the pulmonary or bronchial arteries is an emerging treatment option for large and multifocal lung tumors (Table E1 [online]). Like the liver, the lung has a dual blood supply. However, unlike liver tumors, which are mostly supplied by the hepatic artery, lung tumors can be supplied by either the bronchial artery or pulmonary artery (3). Response rates are 17% after pulmonary artery chemoembolization (4,5) and 39% after bronchial artery chemoembolization (6-8), bland embolization (9), or chemoinfusion (10-12). The highest reported response rates have been seen with primary lung cancer, treated via the bronchial artery (Table E1 [online]).A major limitation of existing studies of lung chemoembolization is the low response rate. We hypothesize that the low response rate is because of the dual blood supply of lung tumors. Lung tumors primarily supplied by the pulmonary artery will presumably have a low response rate to bronchial artery chemoembolization and Background: Lung chemoembolization is an emerging treatment option for lung tumors, but the optimal embolic, drug, and technique are unknown.Purpose: To determine the technical success rate and safety of bronchial or pulmonary artery chemoembolization of lung metastases using ethiodized oil, mitomycin, and microspheres. Materials and Methods:Patients with unresectable and unablatable lung, endobronchial, or mediastinal metastases, who failed systemic chemotherapy, were enrolled in this prospective, single-center, single-arm, phase I clinical trial (December 2019-September 2020). Pulmonary and bronchial angiography was performed to determine the blood supply to the lung metastases. Based on the angiographic findings, bronchial or pulmonary artery chemoembolization was performed using an ethiodized oil and mitomycin emulsion, followed by microspheres. The primary objectives were technical success rate and safety, according to the National Cancer Institute Common Terminology Criteria for Adverse Events. CIs of proportions were estimated with the equal-tailed Jeffreys prior interval, and correlations were evaluated with the Spearman test. Results:Ten participants (median age, 60 years; interquartile range, 52-70 years; six women) were evaluated. Nine of the 10 participants (90%) had lung metastases supplied by the bronchial artery, and one of the 10 participants (10%) had lung metastases supplied by the pulmonary artery. The technical success rate of intratumoral drug delivery was 10 of 10 (100%) (95% CI: 78, 100). There were no severe adverse events (95% CI: 0, 22). The response rate of treated tumors was one of 10 (10%) according to the Response Evaluation Criteria in Solid Tumors and four of 10 (40%) according to the PET Response Criteria in Solid Tumors. Ethiodized oil retention at 4-6 w...

show abstract

Embolization for Lung Tumors

Boas

2024

Interventional Oncology

View full text Add to dashboard Cite

Treatment of pancreatic cancer by intra-arterial injection of an emulsion of Lipiodol and bumetanide (an anti-glycolytic drug) in a porcine model: initial results

Cited by 5 publications

References 0 publications

Induction and characterization of pancreatic cancer in a transgenic pig model

Induction and characterization of pancreatic cancer in a transgenic pig model

Bronchial or Pulmonary Artery Chemoembolization for Unresectable and Unablatable Lung Metastases: A Phase I Clinical Trial

Embolization for Lung Tumors

Contact Info

Product

Resources

About